Gewinn & Umsatz News zur INSULET Aktie

>INSULET Aktienkurs

178.5 EUR -0.1% (TradegateBSX)

Ask: 178.9 EUR / 55 Stück

Bid: 175.35 EUR / 57 Stück

Tagesumsatz: 15 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

INSULET Aktie über LYNX handeln

Intraday

1 Jahr

>INSULET Performance

1 Woche: -2,6%

1 Monat: -14,3%

3 Monate: -25,7%

6 Monate: -32,2%

1 Jahr: -23,2%

laufendes Jahr: -26,9%

>INSULET Aktie

Name:

INSULET CORP. DL -,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US45784P1012 / A0MQX8

Symbol/ Ticker:

GOV (Frankfurt) / PODD (NASDAQ)

Kürzel:

FRA:GOV, ETR:GOV, GOV:GR, NASDAQ:PODD

Index:

Webseite:

https://www.insulet.com/

Profil:

Insulet Corporation is a medical device company that develops, manufactures, and sells innovative insulin delivery systems, primarily through its Omnipod product platform, for people with insulin-dependent diabetes worldwide. The Omnipod offers a tub..
>Volltext..

Marktkapitalisierung:

12626.33 Mio. EUR

Unternehmenswert:

12869.55 Mio. EUR

Umsatz:

2346.15 Mio. EUR

EBITDA:

508.53 Mio. EUR

Nettogewinn:

214.07 Mio. EUR

Gewinn je Aktie:

3.04 EUR

Schulden:

867.96 Mio. EUR

Liquide Mittel:

620.37 Mio. EUR

Operativer Cashflow:

493.19 Mio. EUR

Bargeldquote:

1.05

Umsatzwachstum:

15.23%

Gewinnwachstum:

-47.93%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

INSULET

Letzte Datenerhebung:

04.04.26

>INSULET Kennzahlen

Aktien/ Unternehmen:

Aktien: 70.4 Mio. St.

Frei handelbar: 99.55%

Leerverk. Aktien: 3.63%

Rückkaufquote: 0.18%

Mitarbeiter: 5400

Umsatz/Mitarb.: 0.43 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 75.04%

Bewertung:

KGV: 58.61

KGV lG: 31.82

KUV: 5.76

KBV: 9.53

PEG-Ratio: -

EV/EBITDA: 25.31

Rentabilität:

Bruttomarge: 72.17%

Gewinnmarge: 9.12%

Operative Marge: 17.5%

Managementeffizenz:

Gesamtkaprendite: 7.87%

Eigenkaprendite: 18.12%

>INSULET Peer Group

Gesundheit, Diabetes- & Adipositas- Behandlung, Medizinprodukte & -technik/ Implantate/ Wundpflege

>INSULET Chart & Kurs - NASDAQ

>INSULET Gewinn & Umsatz News

18.02.26 - 13:48	Insulet Corp. Q4 Sales Increase (AFX)
	WASHINGTON (dpa-AFX) - Insulet Corp. (PODD) revealed a profit for fourth quarter of $101.6 millionThe company's earnings totaled $101.6 million, or $1.44 per share. This compares with $102.9 milli......

18.02.26 - 13:18	Insulet beats revenue expectations in fourth quarter, shares rise (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

06.11.25 - 18:48	Insulet Q3 Profit Rises (AFX)
	WASHINGTON (dpa-AFX) - Insulet Corporation (PODD) Thursday reported third-quarter net income of $87.6 million or $1.24 per share, compared with $77.5 million, or $1.08 per share in the prior year.......

06.11.25 - 12:54	Insulet shares rise 4% as Q3 results top estimates, company raises guidance (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

26.08.25 - 14:42	Insulet Stock: Analyst Estimates & Ratings (Barchart)
	Insulet has significantly outpaced the broader market over the past year, and analysts remain very bullish on the stock's prospects....

08.08.25 - 04:24	Insulet Corp. Q2 Profit Decreases, But Beats Estimates (AFX)
	WASHINGTON (dpa-AFX) - Insulet Corp. (PODD) released a profit for second quarter that Decreased from the same period last year but beat the Street estimates.The company's bottom line came in at $2......

24.07.25 - 14:18	What to Expect From Insulets Q2 2025 Earnings Report (Barchart)
	Insulet is expected to release its second-quarter earnings next month, with analysts anticipating double-digit bottom-line growth....

09.05.25 - 00:36	Insulet Posts Mixed Q1 Results With Revenue Growth And Lower Earnings (AFX)
	WASHINGTON (dpa-AFX) - Insulet Corporation (PODD), a medical device company, on Thursday posted its first quarter results for 2025. With a net income of $35.4 million for the first quarter of 2025......

28.04.25 - 14:48	Heres What to Expect From Insulets Next Earnings Report (Barchart)
	Insulet is set to release its first-quarter results next month, and analysts expect a double-digit earnings growth....

20.03.25 - 03:24	Insulet′s RADIANT Trial Results Highlight Significant Glycemic Benefits From Omnipod 5 Transition (AFX)
	WASHINGTON (dpa-AFX) - The RADIANT trial conducted by Insulet Corp. (PODD) highlighted significant glycemic improvements with the use of the Omnipod 5 Automated Insulin Delivery System. These impr......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die Frauen bewundern einen Mann wegen seiner Stärke, aber sie lieben ihn wegen seiner Schwächen. - Beatrice Brown

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram